Weight Loss Drugs: Hurdles and Stock Market Impact

Experts warn that the widespread use of obesity drugs, such as Novo Nordisk's Ozempic, faces major hurdles. While there is strong evidence supporting the drug's ability to delay the progression of chronic kidney disease, data for its use in other conditions like Alzheimer's and alcohol addiction is underdeveloped. Challenges include cost, adherence, and insurance coverage, with some employers and states declining to cover the weight loss indication. However, if the FDA approves Ozempic for use in Type 2 diabetics with chronic kidney disease, it could force insurance companies to expand coverage. Supply constraints and a valuation disconnect between Novo Nordisk, Eli Lilly, and their peers may also impact the growth trend.